Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study identified epidemiological and clinical characteristics of smoldering multiple myeloma (SMM) in a general population for the first time. Based on data from iStopMM’s 75,000 participant cohort, the study’s lead author, Sigrun Thorsteindotter, MD, PhD, and his team reported that the prevalence of SMM in persons aged 40 years or older is 0.53%. ...